NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球膽管癌市場(2021年∼2028年)

Global Bile Duct Cancer Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008251
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
全球膽管癌市場(2021年∼2028年) Global Bile Duct Cancer Market - 2021-2028
出版日期: 2021年05月27日內容資訊: 英文 180 Pages
簡介

膽管癌是一種罕見的疾病,癌細胞在膽管中形成。結腸炎和某些肝臟疾病會使膽管癌的風險增加一倍。膽管癌的跡象包括黃疸和腹痛。膽管癌市場成長的主要因素有全球膽管癌患者人數增加、醫療領域技術進步以及發達國家醫療成本上升。

本報告提供全球膽管癌市場調查,彙整市場概要,市場區隔·各地區的市場規模及成長率的變化與預測,新型冠狀病毒感染疾病(COVID-19)的影響分析,市場成長的推動要素及阻礙因素分析,市場機會,價格及貿易趨勢,競爭情形,主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 市場明細:各類型
  • 市場明細:各治療法
  • 市場明細:各診斷法
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 市場動態

  • 市場影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 新型冠狀病毒感染疾病(COVID-19)的影響分析

  • 新型冠狀病毒感染疾病(COVID-19)的影響分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後的市場方案
  • COVID-19中的價格趨勢
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 總論

第7章 全球膽管癌市場:各類型

  • 簡介
    • 市場規模·與前一年同期比較成長率分析:各類型
    • 市場魅力指數:各類型
  • 肝內膽管癌
    • 簡介
    • 市場規模·成長率分析
  • 肝外膽管癌

第8章 全球膽管癌市場:各治療法

  • 簡介
    • 市場規模·與前一年同期比較成長率分析:各治療法
    • 市場魅力指數:各治療法
  • 標靶治療
    • 簡介
    • 市場規模·成長率分析
  • 免疫療法
  • 放射治療
  • 化療

第9章 全球膽管癌市場:各診斷法

  • 簡介
    • 市場規模·與前一年同期比較成長率分析:各診斷法
    • 市場魅力指數:各診斷法
  • 血液檢驗
    • 簡介
    • 市場規模·成長率分析
  • 腹部成像
  • 手術
  • MRI
  • 其他

第10章 全球膽管癌市場:各終端用戶

  • 簡介
    • 市場規模·與前一年同期比較成長率分析:各終端用戶
    • 市場魅力指數:各終端用戶
  • 醫院
    • 簡介
    • 市場規模·成長率分析
  • 診療所
  • 門診外科中心

第11章 全球膽管癌市場:各地區

  • 簡介
    • 市場規模分析·與前一年同期比較成長率:各地區
    • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類型
    • 市場規模·與前一年同期比較成長率:不同治療
    • 市場規模·與前一年同期比較成長率:診斷法
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 歐洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類型
    • 市場規模·與前一年同期比較成長率:不同治療
    • 市場規模·與前一年同期比較成長率:診斷法
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 南美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類型
    • 市場規模·與前一年同期比較成長率:不同治療
    • 市場規模·與前一年同期比較成長率:診斷法
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 亞太地區
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類型
    • 市場規模·與前一年同期比較成長率:不同治療
    • 市場規模·與前一年同期比較成長率:診斷法
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 中東·非洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各類型
    • 市場規模·與前一年同期比較成長率:不同治療
    • 市場規模·與前一年同期比較成長率:診斷法
    • 市場規模·與前一年同期比較成長率:各終端用戶

第12章 競爭情形

  • 主要策略·發展趨勢
  • 企業佔有率分析
  • 產品基準

第13章 企業簡介

  • Johnson & Johnson
    • 企業概要
    • 產品系列
    • 主要的焦點
    • 財務形勢
  • Bayer AG
  • Celgene Corp
  • Bristol-Myers Squibb
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.,
  • Boston Scientific Corporation

第14章 關於DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global bile duct cancer market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Bile duct cancer is an uncommon disorder in which cancer cells form in the bile ducts. Having colitis or specific liver diseases can double the risk of bile duct cancer. Signs of bile duct cancer involve jaundice and pain in the abdomen. Bile duct cancer, also known as cholangiocarcinomas, begins in a bile duct.

Nearly all bile duct malignancies are cholangiocarcinomas. These cancers are a type of adenocarcinoma, which is cancer that rises in gland cells. Cholangiocarcinomas start in the gland cells that line the lining of the ducts.

Procedures that make the images of bile ducts and the surrounding area help diagnose bile duct cancer and show how far cancer has spread. The bile duct cancer can be removed by surgery. Tests and methods to detect, diagnose, and stage bile duct cancer are usually done simultaneously.

Market Dynamics

The bile duct cancer market growth is driven by increase in the prevalence of bile duct cancer patients across the globe, technological advancement in the health care sector, and a rise in health care expenditure in developed countries. The change in the current lifestyle has led to the exposure of a large population to certain risk factors that contribute to Bile Duct Cancer Market in the forecast period.

Increasing prevalence and incidence of cancer worldwide in the elderly population

As per the NCI, in 2014, an estimated 66,771 people lived with bile duct cancer in the U.S. Moreover, the disease is exacted to cause 28,920 deaths at the end of 2017, estimating 4.8% of all cancer deaths. Rates for new intrahepatic bile duct cancer cases have grown by an average of 2.7% each year across the last ten years. Death rates have been estimated to have increased by an average of 2.6% each year over 2005-2014. Such a rise in the prevalence of bile duct cancer has driven the growth of the market.

The increasing prevalence of diseases such as liver fluke will significantly escalate the demand for bile duct cancer treatment in healthcare institutions. Such factors are likely to positively impact the global bile duct cancer market's growth during the predicted period. Moreover, increasing exposure to harmful chemicals for printing and other applications is affecting the industrial workers adversely. Due to such factors, bile duct cancer treatment is likely to increase demand across various healthcare industries.

Rising modern diagnostic facilities for the detection of bile duct cancer is driving the market growth

A precise and detailed bile duct cancer diagnosis is the first step in devising a bile duct cancer treatment. Several lab tests are available to check for abnormalities in the bile duct, including blood counts of bilirubin, albumin, alkaline phosphatase, aspartate transaminase (AST), alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT). High levels of these elements in the blood indicate problems with the bile duct, gallbladder or liver.

Endoscopic ultrasound may help the doctor see more precise pictures of the bile duct. A thin, glowing tube with a small video camera is inserted through the mouth and esophagus into the small intestines near the bile duct. In rare cases, a laparoscopic ultrasound, through small holes in the front of the abdomen, may be used to check the bile duct and other internal organs. Thus, an increasing focus on these lab tests for treating the infection drives the market growth in the forecast period.

Side effects associated with medications coupled with high cost of cancer treatment

The American Society of Clinical Oncology states that there is a yawning gap between cancer treatment costs in the developed and developing countries. Moreover, the US, importing prescription medicines from the foreign countries is not allowed. Also, Patented Medicine Prices Review Board of the government of Canada states that people in the US end up paying more than 100% than any of their counterparts for patented drugs.These variations in prices are likely to hinder the bile duct cancer treatment market.

Side-effects such as radiation therapy can bring hair loss (sometimes called alopecia) to the part of the body receiving radiation. At the same time, chemotherapy can lead to hair loss in the head, scalp, and other body parts. Various chemotherapy medications can cause several types of hair loss or no hair loss at all. Hair loss usually happens within two weeks of treatment, worsening over the first month or two of ongoing treatment.

COVID-19 Impact Analysis

COVID-19 pandemic on bile duct cancer care decreased, and delays in identifying new bile duct cancers and treatment delivery. These problems, if unmitigated, will increase cancer morbidity and mortality in the forecast period. While the immediate care and access disruptions associated with the COVID-19 pandemic have received growing attention in certain areas, the full range of cancer screenings and treatment gaps is not yet well understood or well documented throughout the world comprehensively.

Many healthcare providers accommodated short-term adjustments to cancer care delivery, such as temporarily discontinuing nonemergent cancer screenings, shifting the delivery of care and delaying surgeries and other in-office cancer services to reduce transmission risk, build hospital capacity in anticipation of increasing rates of coronavirus infections, and comply with state regulations and guidelines from the CDC.

Segment Analysis

By type, the bile duct cancer market is classified into intrahepatic bile duct cancer and extrahepatic bile duct cancer.

Intrahepatic Bile Duct Cancer segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Intrahepatic bile duct cancer is a rare type of cancer. It begins in the small bile duct sections that carry bile inside the liver. Only about 5 to 10 percent of bile duct cancers are categorized as intrahepatic, and some are misdiagnosed as liver cancer.

The expanse of a patient's intrahepatic bile duct cancer will affect how it is treated, amongst other factors like age and overall health. Patients with early-stage malignancies often have resection surgery to remove the altered bile duct and encompass lymph nodes. Radiation therapy and chemotherapy may also be used to attack cancer cells. Some later-stage bile duct cancers may not be surgically detachable, in which case a combination of radiation therapy, chemotherapy and radiofrequency ablation may be used to decrease symptoms.

Extrahepatic bile duct cancer is a rare disease in which dangerous cancer cells form in the bile duct outside the liver. Various types of therapy are available for patients with extrahepatic bile duct cancer. Some procedures are standard, and some are being tested in clinical trials. When clinical trials confirm that a new treatment is more valuable than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Based on therapy, the Bile Duct Cancer Market is classified into targeted therapy, radiation therapy, immunotherapy, chemotherapy.

On the basis of therapy, the the bile duct cancer market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.

The chemotherapy segment are expected to dominate the bile duct cancer market during the forecast period

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Geographical Analysis

North America region holds the largest market share in the global Bile Duct Cancer Market

North America region is dominating the global Bile Duct Cancer Market accounted for the largest market share in 2020, owing to the presence of a robust healthcare infrastructure that supports innovations. Also, general awareness among people about personal health is more significant than in other regions of the world. Most novel technology, be that diagnostic or therapeutic, comes from these regions. Also, an increasing geriatric population here helps growth in this market.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

Competitive Landscape

The bile duct cancer market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Bayer AG, Celgene Corp, Bristol-Myers Squibb, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Merck & Co., Inc., ConMed Corporation, and Boston Scientific Corporation. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the bile duct cancer market globally.

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the bile duct cancer market segmentation by type, therapy, diagnosis, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in bile duct cancer market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of bile duct cancer market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global bile duct cancer market report would provide an access to an approx. 69 market data table, 64 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Bile Duct Cancer Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Bile Duct Cancer Market - Market Definition and Overview

3. Global Bile Duct Cancer Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Therapy
  • 3.3. Market Snippet by Diagnosis
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Bile Duct Cancer Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising modern diagnostic facilities for the detection of bile duct cancer is driving the market growth
      • 4.1.1.2. Increasing prevalence and incidence of cancer worldwide in the elderly population
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with medications coupled with high cost of cancer treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Bile Duct Cancer Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Bile Duct Cancer Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Bile Duct Cancer Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Intrahepatic Bile Duct Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.3. Extrahepatic Bile Duct Cancer

8. Global Bile Duct Cancer Market - By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 8.1.2. Market Attractiveness Index, By Therapy
  • 8.2. Targeted Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Immunotherapy
  • 8.4. Radiation Therapy
  • 8.5. Chemotherapy

9. Global Bile Duct Cancer Market - By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 9.1.2. Market Attractiveness Index, By Diagnosis
  • 9.2. Blood Tests*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Abdominal Imaging
  • 9.4. Surgery
  • 9.5. MRI
  • 9.6. Others

10. Global Bile Duct Cancer Market - By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers

11. Global Bile Duct Cancer Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Bile Duct Cancer Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Global Bile Duct Cancer Market- Company Profiles

  • 13.1. Johnson & Johnson *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bayer AG
  • 13.3. Celgene Corp
  • 13.4. Bristol-Myers Squibb
  • 13.5. Pfizer, Inc.
  • 13.6. F. Hoffmann-La Roche Ltd.
  • 13.7. Sanofi
  • 13.8. Novartis AG
  • 13.9. Merck & Co., Inc.,
  • 13.10. Boston Scientific Corporation

LIST NOT EXHAUSTIVE

14. Global Bile Duct Cancer Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us